In 2022, over 33 percent of both men and women in the United States reported themselves as obese (BMI over 30), making it the country with the highest percentage of obese adults on this list. Other selected countries on the list with a high prevalence of obesity among adults included the United Kingdom and Australia. Obesity groups in the United States In 2022, Black adults had the highest overweight and obesity rates of any race or ethnicity in the United States. Asians and Native Hawaiians or Pacific Islanders had the lowest rates by far, with roughly 14 percent. In 2021, about 30 percent of people aged 65 and older were obese in the United States. This estimate has been steadily increasing since 2013 when roughly 27 percent of elderly Americans were obese. Leading health problems worldwide Obesity was considered one of 2023’s biggest health problems: 25 percent of adults worldwide stated that obesity was the biggest health issue for people within their country. Around 44 percent of adults stated that mental health was the most significant problem facing their country that year.
Portugal had the highest prevalence of diabetes in Europe among their adult population with **** percent living with diabetes, as of 2024, Croatia followed with the second-highest share at **** percent. Conversely, Ireland was the country with the lowest prevalence of diabetes in Europe at *** percent. Diabetes-related deaths The highest number of diabetes-related deaths in Europe, at almost ******, was recorded in Germany in 2024. Italy and France followed, with roughly *******and ****** deaths, respectively. Diabetes risk factors in Europe One of the major contributing factors to type 2 diabetes is being overweight or obese. As of 2022, Greece had the highest share of overweight population across Europe, with *****percent. The lack of sports and exercise is also another risk factor. As of 2022, Portugal was the European country with the highest share of people never exercising or engaging in sports, with ** percent.
https://www.wiseguyreports.com/pages/privacy-policyhttps://www.wiseguyreports.com/pages/privacy-policy
BASE YEAR | 2024 |
HISTORICAL DATA | 2019 - 2024 |
REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
MARKET SIZE 2023 | 247.58(USD Billion) |
MARKET SIZE 2024 | 261.14(USD Billion) |
MARKET SIZE 2032 | 400.0(USD Billion) |
SEGMENTS COVERED | Product Type, Dietary Approach, Distribution Channel, End User, Regional |
COUNTRIES COVERED | North America, Europe, APAC, South America, MEA |
KEY MARKET DYNAMICS | Increasing obesity prevalence, Rising health consciousness, Technological advancements in treatments, Growing demand for weight loss products, Expansion of wellness programs |
MARKET FORECAST UNITS | USD Billion |
KEY COMPANIES PROFILED | Herbalife, SlimFast, Nutrisystem, Snap Kitchen, Poshmark, Noom, MyFitnessPal, Jenny Craig, Weight Watchers, Lean Cuisine, Medifast, WW International, Bariatric Partners, Optavia, Keto and Co |
MARKET FORECAST PERIOD | 2025 - 2032 |
KEY MARKET OPPORTUNITIES | Personalized weight loss programs, Digital health technology integration, Increased demand for natural supplements, Growth in fitness wearables market, Expansion of telehealth services |
COMPOUND ANNUAL GROWTH RATE (CAGR) | 5.48% (2025 - 2032) |
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
S1 Table. Prevalence of HPF within Food Main Categories across Countries. S2 Table. Summary of the Prevalence of HPF across Countries.S3 Table. Logistic regression results for the HPF prevalence compared to United States. S4 Table. Logistic regression results for the FSOD prevalence compared to United States. S5 Table. Logistic regression results for the FS prevalence compared to United States. S6 Table. Logistic regression results for the CSOD prevalence compared to United States. S7 Table. Descriptive Statistics of Nutritional Compositions of FSOD across Countries.S8 Table. Descriptive Statistics of Nutritional Compositions of FS across Countries. S9 Table. Descriptive Statistics of Nutritional Compositions of CSOD across Countries. S10 Table. Ordered Beta Regression Results for nutritional compositions of FSOD across countries compared to United States.S11 Table. Ordered Beta Regression Results for nutritional compositions of FS across countries compared to United States. S12 Table. Ordered Beta Regression Results for nutritional compositions of CSOD across countries compared to United States. S13 Table. Distinct and Overlapping percentage of HPF and UPF across countries. (ZIP)
https://www.wiseguyreports.com/pages/privacy-policyhttps://www.wiseguyreports.com/pages/privacy-policy
BASE YEAR | 2024 |
HISTORICAL DATA | 2019 - 2024 |
REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
MARKET SIZE 2023 | 25.45(USD Billion) |
MARKET SIZE 2024 | 26.92(USD Billion) |
MARKET SIZE 2032 | 42.3(USD Billion) |
SEGMENTS COVERED | Health Concerns ,Target Consumers ,Product Types ,Packaging Formats ,Regional |
COUNTRIES COVERED | North America, Europe, APAC, South America, MEA |
KEY MARKET DYNAMICS | Rising health consciousness Increasing prevalence of diabetes Growing vegan and vegetarian population Increasing demand for functional foods Expansion of ecommerce |
MARKET FORECAST UNITS | USD Billion |
KEY COMPANIES PROFILED | Yakult Honsha ,Mengniu Dairy ,Fonterra ,Chobani ,Nestle ,Unilever ,Dean Foods ,Muller Group ,Lactalis Group ,Yili Group ,Danone ,Arla Foods ,Meiji Dairies Corporation ,Stonyfield Farm |
MARKET FORECAST PERIOD | 2025 - 2032 |
KEY MARKET OPPORTUNITIES | 1 Rising health consciousness and adoption of healthy diets 2 Growing demand for products with reduced sugar and fat content 3 Increasing prevalence of lactose intolerance and milk allergies 4 Expansion into emerging markets with rising disposable incomes 5 Product innovation and the introduction of new flavors and ingredients |
COMPOUND ANNUAL GROWTH RATE (CAGR) | 5.81% (2025 - 2032) |
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
S1 Fig. Data Source Composition by Country. S2 Fig. The Proportion of Main Food Category within Each Sampled Country. S3 Fig. Prevalence of HPF groups within Food Main Categories across Countries. S4 Fig. 95% Confidence Interval for Odds Ratio of food items being FSOD compared to United States. S5 Fig. 95% Confidence Interval for Odds Ratio of food items being FS compared to United States.S6 Fig. 95% Confidence Interval for Odds Ratio of food items being CSOD compared to United States.S7 Fig. Boxplot for the nutritional compositions of FSOD across countries.S8 Fig. Boxplot for the nutritional compositions of FS across countries.S9 Fig. Boxplot for the nutritional compositions of CSOD across countries. S10 Fig. 95% Confidence intervals plot for nutritional compositions of FSOD compared to the United States.S11 Fig. Confidence intervals plot for nutritional compositions of FS compared to the United States.S12 Fig. Confidence intervals plot for nutritional compositions of CSOD compared to the United States. S13 Fig. Distinct and overlapping prevalence between HPF and UPF across countries within food main categories. (ZIP)
https://www.wiseguyreports.com/pages/privacy-policyhttps://www.wiseguyreports.com/pages/privacy-policy
BASE YEAR | 2024 |
HISTORICAL DATA | 2019 - 2024 |
REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
MARKET SIZE 2023 | 22.94(USD Billion) |
MARKET SIZE 2024 | 25.06(USD Billion) |
MARKET SIZE 2032 | 50.84(USD Billion) |
SEGMENTS COVERED | Administration, Indication, Molecular Weight, Mechanism of Action, Regional |
COUNTRIES COVERED | North America, Europe, APAC, South America, MEA |
KEY MARKET DYNAMICS | Rising prevalence of diabetes Technological advancements Increasing adoption of GLP1 receptor agonists Government initiatives Growing demand for personalized medicine |
MARKET FORECAST UNITS | USD Billion |
KEY COMPANIES PROFILED | Eli Lilly and Company, AbbVie Inc., Johnson & Johnson, Amgen Inc., Merck & Co., Inc., Pfizer Inc., Novo Nordisk A/S, Intarcia Therapeutics, Inc., AstraZeneca plc, Albireo Pharma, Inc., Gilead Sciences, Inc., Takeda Pharmaceutical Company Limited, Boehringer Ingelheim GmbH, Sanofi S.A. |
MARKET FORECAST PERIOD | 2025 - 2032 |
KEY MARKET OPPORTUNITIES | Rising prevalence of diabetes Technological advancements Expanding obesity rates Growing demand for personalized medicine Increasing healthcare expenditure |
COMPOUND ANNUAL GROWTH RATE (CAGR) | 9.25% (2025 - 2032) |
Diabetes prevalence in Malawi, at 5.5%, is comparable to high-income countries (HIC) in Europe, despite a relatively low prevalence of obesity and physical inactivity. Approximately 40% of Malawians with diabetes have 'normal' BMIs. We hypothesised that a combination of sub-optimal nutrition in utero and/or childhood and high levels of exposure to infection which together contribute to low muscle mass and strength are likely to contribute to a different diabetes risk phenotype in Malawians compared to those in HIC. Thus interventions, focused on weight loss and increased physical activity, which have been effective at preventing diabetes in HIC may not be effective in Malawi and a shift towards nutritional interventions focused on increasing muscle mass & strength and reducing inflammation was likely a more effective approach. Our long-term aim was therefore to develop and implement effective and pragmatic large-scale nutritional interventions optimized to prevent diabetes in Malawians at elevated diabetes risk. The overall aim of this project was to undertake key initial steps to facilitate the development of such interventions. Our first objective was to increase understanding of the links between nutritional intake and status, and the physical, metabolic and inflammatory phenotype in Malawian adults at increased risk of diabetes. To achieve this we recruited 50 participants (25 from rural and 25 from urban areas) with pre-diabetes and an equivalent number of age- and sex- matched healthy participants (25 rural and 25 urban) and make measurements of dietary intake, body composition, grip strength, physical activity levels, cardiometabolic risk profile (glucose, HbA1c, lipids, insulin, blood pressure), gut microbiota and inflammatory markers (detailed below). This enabled detailed characterization of the Malawian 'pre-diabetes' phenotype and identification of aspects of dietary intake which could potentially be altered in nutritional interventions to reduce diabetes risk. Our second aim was to explore nutritional practices and understandings of diabetes in urban and rural communities in Malawi, and consider which nutritional practices might be amenable to changes likely to reduce risk of developing diabetes. To achieve this we undertook secondary analysis of existing interview, focus group and observational qualitative data collected by MEIRU during studies investigating salt intake and diabetes medication adherence in Malawi [NHRSC protocol ~1425], and supplemented this with primary data collection (via focus groups) to explore nutritional and physical activity (exercise) practices and understandings of diabetes in urban and rural communities in Malawi, and considered which nutritional and physical activity practices might be amenable to changes likely to reduce risk of developing diabetes.
NHSRC number: 18/01/1951
Lilongwe
Individual
In this initial project, funded to promote development of nutritional research around NCD and develop partnerships, we had no prior data on expected prevalence of most of the outcome measures in pre-diabetic participants as this group was not studied in this setting before. We do have data on the prevalence of obesity in these groups from our baseline NCD survey. We expected other abnormal indices to have similar magnitudes of difference, but had no data available for sample size calculations at this stage. It was likely that this hypothesis generating study would generate good estimates of risk that can support sample size calculations for an intervention trial which was the long term goal. Our study size was 50 pre-diabetics and 50 age-sex matched participants will have 93% power to detect the observed difference in obesity rates between the two groups (8% healthy, 35% pre-diabetic have BMI > 30kg/m2)):
alpha = 0.0500 (one-sided) p1 = 0.0800 p2 = 0.3500 sample size n1 = 50 n2 = 50 n2/n1 = 1.00 Estimated power: power = 0.9306
Face-to-face [f2f]
NUT study used a number of questionnaires including the following: Weighed food records which was used to determine the amount of food that was consumed by the participants. This questionnaire helped in the validation of a food frequency questionnaire (FFQ) which was the used for a similar purpose in the main study. The study also used a multi-pass food frequency questionnaire which works in a similar way as the food frequency questionnaire. Other questionnaires include Health history questionnaire which basically asks how active the participants were during the study period and the data from this questionnaire helps to check how healthy the participants were during the entire study period.
Blood pressure , Grip strength, Skinfold thickness and ECG were also used to check for cardiovascular health, strength of both hands, the amount of fat mass and body composition respectively.
All the questionnaires were formed in English and later translated into Chichewa and Tumbuka depending on the site of the study. Anthropometric measurements and stool samples were collected from all study participants to help the laboratory team check for gut micro biota that relates to consumption of food which may protect or predispose a person to diabetes.
Diabetes prevalence in Malawi, at 5.5%, is comparable to high-income countries (HIC) in Europe, despite a relatively low prevalence of obesity and physical inactivity. Approximately 40% of Malawians with diabetes have 'normal' BMIs. We hypothesised that a combination of sub-optimal nutrition in utero and/or childhood and high levels of exposure to infection which together contribute to low muscle mass and strength are likely to contribute to a different diabetes risk phenotype in Malawians compared to those in HIC. Thus interventions, focused on weight loss and increased physical activity, which have been effective at preventing diabetes in HIC may not be effective in Malawi and a shift towards nutritional interventions focused on increasing muscle mass & strength and reducing inflammation was likely a more effective approach. Our long-term aim was therefore to develop and implement effective and pragmatic large-scale nutritional interventions optimized to prevent diabetes in Malawians at elevated diabetes risk. The overall aim of this project was to undertake key initial steps to facilitate the development of such interventions. Our first objective was to increase understanding of the links between nutritional intake and status, and the physical, metabolic and inflammatory phenotype in Malawian adults at increased risk of diabetes. To achieve this we recruited 50 participants (25 from rural and 25 from urban areas) with pre-diabetes and an equivalent number of age- and sex- matched healthy participants (25 rural and 25 urban) and make measurements of dietary intake, body composition, grip strength, physical activity levels, cardiometabolic risk profile (glucose, HbA1c, lipids, insulin, blood pressure), gut microbiota and inflammatory markers (detailed below). This enabled detailed characterization of the Malawian 'pre-diabetes' phenotype and identification of aspects of dietary intake which could potentially be altered in nutritional interventions to reduce diabetes risk. Our second aim was to explore nutritional practices and understandings of diabetes in urban and rural communities in Malawi, and consider which nutritional practices might be amenable to changes likely to reduce risk of developing diabetes. To achieve this we undertook secondary analysis of existing interview, focus group and observational qualitative data collected by MEIRU during studies investigating salt intake and diabetes medication adherence in Malawi [NHRSC protocol ~1425], and supplemented this with primary data collection (via focus groups) to explore nutritional and physical activity (exercise) practices and understandings of diabetes in urban and rural communities in Malawi, and considered which nutritional and physical activity practices might be amenable to changes likely to reduce risk of developing diabetes.
NHSRC number: 18/01/1951
Chilumba
Individual
In this initial project, funded to promote development of nutritional research around NCD and develop partnerships, we had no prior data on expected prevalence of most of the outcome measures in pre-diabetic participants as this group was not studied in this setting before. We do have data on the prevalence of obesity in these groups from our baseline NCD survey. We expected other abnormal indices to have similar magnitudes of difference, but had no data available for sample size calculations at this stage. It was likely that this hypothesis generating study would generate good estimates of risk that can support sample size calculations for an intervention trial which was the long term goal. Our study size was 50 pre-diabetics and 50 age-sex matched participants will have 93% power to detect the observed difference in obesity rates between the two groups (8% healthy, 35% pre-diabetic have BMI > 30kg/m2)):
alpha = 0.0500 (one-sided) p1 = 0.0800 p2 = 0.3500 sample size n1 = 50 n2 = 50 n2/n1 = 1.00 Estimated power: power = 0.9306
Face-to-face [f2f]
NUT study used a number of questionnaires including the following: Weighed food records which was used to determine the amount of food that was consumed by the participants. This questionnaire helped in the validation of a food frequency questionnaire (FFQ) which was the used for a similar purpose in the main study. The study also used a multi-pass food frequency questionnaire which works in a similar way as the food frequency questionnaire. Other questionnaires include Health history questionnaire which basically asks how active the participants were during the study period and the data from this questionnaire helps to check how healthy the participants were during the entire study period.
Blood pressure , Grip strength, Skinfold thickness and ECG were also used to check for cardiovascular health, strength of both hands, the amount of fat mass and body composition respectively.
All the questionnaires were formed in English and later translated into Chichewa and Tumbuka depending on the site of the study. Anthropometric measurements and stool samples were collected from all study participants to help the laboratory team check for gut micro biota that relates to consumption of food which may protect or predispose a person to diabetes.
According to our latest research, the global Endolumenal Magnetic Compression Jejunal Side-Bypass market size reached USD 412 million in 2024, reflecting robust momentum driven by innovations in minimally invasive gastrointestinal procedures. The market is anticipated to expand at a CAGR of 14.8% from 2025 to 2033, with forecasts indicating a value of USD 1,263 million by 2033. Key growth factors include increasing prevalence of obesity and type 2 diabetes, rising demand for less invasive surgical options, and ongoing advancements in magnetic compression technology.
The primary growth driver for the Endolumenal Magnetic Compression Jejunal Side-Bypass market is the escalating global burden of obesity and related metabolic disorders, particularly type 2 diabetes. As per the World Health Organization, over 650 million adults were obese in 2024, and this number is projected to rise further. This epidemiological trend has intensified the demand for innovative, less invasive interventions that can offer effective and durable weight loss and glycemic control. The Endolumenal Magnetic Compression Jejunal Side-Bypass procedure, with its minimally invasive profile and promising clinical outcomes, is increasingly being adopted as an alternative to traditional bariatric surgeries. Its ability to reduce surgical trauma, shorten recovery times, and minimize perioperative complications is highly valued by both patients and healthcare providers, thereby fueling market expansion.
Technological advancements in magnetic compression devices are another significant growth catalyst. The integration of high-strength, biocompatible magnets and precision-engineered delivery systems has enhanced the safety, efficacy, and reproducibility of jejunal side-bypass procedures. Ongoing research and development efforts focus on optimizing device design, improving procedural workflow, and expanding indications for use. Furthermore, the emergence of next-generation accessories and adjunct technologies, such as real-time imaging and navigation systems, is expected to further streamline the procedure and improve patient outcomes. These innovations are not only broadening the procedural appeal among surgeons but are also attracting investments from major medical device manufacturers, thereby accelerating market growth.
A favorable reimbursement landscape and growing awareness among healthcare professionals about the benefits of endolumenal magnetic compression techniques are also contributing to the market’s upward trajectory. Several countries, particularly in North America and Europe, have introduced reimbursement codes for minimally invasive gastrointestinal procedures, making these interventions more accessible to patients. Simultaneously, professional societies and academic institutions are actively promoting clinical training and education on novel endolumenal techniques, which is enhancing procedural adoption rates. Additionally, the increasing availability of these procedures in ambulatory surgical centers and specialty clinics is improving patient access, further driving market penetration.
From a regional perspective, North America currently dominates the Endolumenal Magnetic Compression Jejunal Side-Bypass market, accounting for the largest revenue share in 2024. This leadership is attributed to high obesity prevalence, advanced healthcare infrastructure, and early adoption of innovative surgical technologies. Europe follows closely, driven by supportive regulatory frameworks and growing investments in minimally invasive surgery. Meanwhile, the Asia Pacific region is emerging as a high-growth market, fueled by rapidly rising obesity rates, expanding healthcare expenditure, and increasing awareness of minimally invasive bariatric procedures. Latin America and the Middle East & Africa, while currently representing smaller shares, are expected to witness accelerated growth over the forecast period as healthcare infrastructure improves and patient demand for advanced gastrointestinal interventions rises.
Not seeing a result you expected?
Learn how you can add new datasets to our index.
In 2022, over 33 percent of both men and women in the United States reported themselves as obese (BMI over 30), making it the country with the highest percentage of obese adults on this list. Other selected countries on the list with a high prevalence of obesity among adults included the United Kingdom and Australia. Obesity groups in the United States In 2022, Black adults had the highest overweight and obesity rates of any race or ethnicity in the United States. Asians and Native Hawaiians or Pacific Islanders had the lowest rates by far, with roughly 14 percent. In 2021, about 30 percent of people aged 65 and older were obese in the United States. This estimate has been steadily increasing since 2013 when roughly 27 percent of elderly Americans were obese. Leading health problems worldwide Obesity was considered one of 2023’s biggest health problems: 25 percent of adults worldwide stated that obesity was the biggest health issue for people within their country. Around 44 percent of adults stated that mental health was the most significant problem facing their country that year.